Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease
Background/Aims. While biological drugs are useful for relieving the disease activity and preventing abdominal surgery in patients with Crohn’s disease (CD), it is unclear whether the use of biological drugs in CD patients with no history of abdominal surgery is appropriate. We evaluated the effects...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2013-01, Vol.2013 (2013), p.1-5 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5 |
|---|---|
| container_issue | 2013 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2013 |
| creator | Okamoto, Kotaro Tanabe, Hiroki Ohtake, Takaaki Kono, Toru Furukawa, Hiroyuki Ashida, Toshifumi Kohgo, Yutaka Moriichi, Kentaro Tominaga, Motoya Kashima, Shin Ueno, Nobuhiro Inaba, Yuhei Ito, Takahiro Fujiya, Mikihiro Sakatani, Aki Ikuta, Katsuya |
| description | Background/Aims. While biological drugs are useful for relieving the disease activity and preventing abdominal surgery in patients with Crohn’s disease (CD), it is unclear whether the use of biological drugs in CD patients with no history of abdominal surgery is appropriate. We evaluated the effects of infliximab and other factors on extending the duration until the first surgery in CD patients on a long-term basis. Methods. The clinical records of 104 CD patients were retrospectively investigated. The cumulative nonoperation rate until the first surgery was examined with regard to demographic factors and treatments. Results. The 50% nonoperative interval in the 104 CD patients was 107 months. The results of a univariate analysis revealed that a female gender, the colitis type of CD, and the administration of corticosteroids, immunomodulators, or infliximab were factors estimated to improve the cumulative nonoperative rate. A multivariate analysis showed that the colitis type and administration of infliximab were independent factors associated with a prolonged interval until the first surgery in the CD patients with no history of abdominal surgery. Conclusions. This study suggests that infliximab treatment extends the duration until the first surgery in CD patients with no history of abdominal surgery. The early use of infliximab before a patient undergoes abdominal surgery is therefore appropriate. |
| doi_str_mv | 10.1155/2013/879491 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3858862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490730887</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-ab91fa2a4e2e46d4aa9f4220ed8f3857997f446c26daf4f3d9b878037d9945023</originalsourceid><addsrcrecordid>eNqNkc1OGzEURq2qiCBgxb7yErVK8d_M2BukKiSAhFQkYMPGcmauGVcTD7U9Jex4DV6PJ8FpaER3eGPLPjq-934IHVDyndKiOGKE8iNZKaHoJ7TDOBXjkgr6eXPmfIT2Y_xF8pK0JKrcRiMmeEUlL3bQ7bm3nVu6hZnj6TKBbyJOLeCTIZjkeo8Hn1z392rmQkz4agh3EB6x8_gyE-BTxA8utXgS-ta_PD1HfOIimAh7aMuaLsL-276LbmbT68nZ-OLn6fnkx8W4FpKnsZkrag0zAhiIshHGKCsYI9BIy2VRKVVZIcqalY2xwvJGzWUlCa8apURBGN9Fx2vv_TBfQFPnkoLp9H3ITYVH3Run_3_xrtV3_R-d7VKWK8HhmyD0vweISS9crKHrjId-iJoKRSpOpKwy-m2N1qGPMYDdfEOJXgWiV4HodSCZ_vK-sg37b_wZ-LoGWucb8-A-ZoOMgDXvYE5Jwfgr9ISeIg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490730887</pqid></control><display><type>article</type><title>Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Okamoto, Kotaro ; Tanabe, Hiroki ; Ohtake, Takaaki ; Kono, Toru ; Furukawa, Hiroyuki ; Ashida, Toshifumi ; Kohgo, Yutaka ; Moriichi, Kentaro ; Tominaga, Motoya ; Kashima, Shin ; Ueno, Nobuhiro ; Inaba, Yuhei ; Ito, Takahiro ; Fujiya, Mikihiro ; Sakatani, Aki ; Ikuta, Katsuya</creator><contributor>Kuramochi, Hidekazu</contributor><creatorcontrib>Okamoto, Kotaro ; Tanabe, Hiroki ; Ohtake, Takaaki ; Kono, Toru ; Furukawa, Hiroyuki ; Ashida, Toshifumi ; Kohgo, Yutaka ; Moriichi, Kentaro ; Tominaga, Motoya ; Kashima, Shin ; Ueno, Nobuhiro ; Inaba, Yuhei ; Ito, Takahiro ; Fujiya, Mikihiro ; Sakatani, Aki ; Ikuta, Katsuya ; Kuramochi, Hidekazu</creatorcontrib><description>Background/Aims. While biological drugs are useful for relieving the disease activity and preventing abdominal surgery in patients with Crohn’s disease (CD), it is unclear whether the use of biological drugs in CD patients with no history of abdominal surgery is appropriate. We evaluated the effects of infliximab and other factors on extending the duration until the first surgery in CD patients on a long-term basis. Methods. The clinical records of 104 CD patients were retrospectively investigated. The cumulative nonoperation rate until the first surgery was examined with regard to demographic factors and treatments. Results. The 50% nonoperative interval in the 104 CD patients was 107 months. The results of a univariate analysis revealed that a female gender, the colitis type of CD, and the administration of corticosteroids, immunomodulators, or infliximab were factors estimated to improve the cumulative nonoperative rate. A multivariate analysis showed that the colitis type and administration of infliximab were independent factors associated with a prolonged interval until the first surgery in the CD patients with no history of abdominal surgery. Conclusions. This study suggests that infliximab treatment extends the duration until the first surgery in CD patients with no history of abdominal surgery. The early use of infliximab before a patient undergoes abdominal surgery is therefore appropriate.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2013/879491</identifier><identifier>PMID: 24371835</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Abdomen - physiopathology ; Abdomen - surgery ; Adolescent ; Adult ; Aged ; Antibodies, Monoclonal - administration & dosage ; Child ; Clinical Study ; Crohn Disease - drug therapy ; Crohn Disease - physiopathology ; Crohn Disease - surgery ; Female ; Humans ; Infliximab ; Male ; Middle Aged ; Preoperative Period ; Treatment Outcome</subject><ispartof>BioMed research international, 2013-01, Vol.2013 (2013), p.1-5</ispartof><rights>Copyright © 2013 Aki Sakatani et al.</rights><rights>Copyright © 2013 Aki Sakatani et al. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-ab91fa2a4e2e46d4aa9f4220ed8f3857997f446c26daf4f3d9b878037d9945023</citedby><cites>FETCH-LOGICAL-c483t-ab91fa2a4e2e46d4aa9f4220ed8f3857997f446c26daf4f3d9b878037d9945023</cites><orcidid>0000-0002-4321-7774 ; 0000-0001-5448-4766</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858862/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858862/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24371835$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kuramochi, Hidekazu</contributor><creatorcontrib>Okamoto, Kotaro</creatorcontrib><creatorcontrib>Tanabe, Hiroki</creatorcontrib><creatorcontrib>Ohtake, Takaaki</creatorcontrib><creatorcontrib>Kono, Toru</creatorcontrib><creatorcontrib>Furukawa, Hiroyuki</creatorcontrib><creatorcontrib>Ashida, Toshifumi</creatorcontrib><creatorcontrib>Kohgo, Yutaka</creatorcontrib><creatorcontrib>Moriichi, Kentaro</creatorcontrib><creatorcontrib>Tominaga, Motoya</creatorcontrib><creatorcontrib>Kashima, Shin</creatorcontrib><creatorcontrib>Ueno, Nobuhiro</creatorcontrib><creatorcontrib>Inaba, Yuhei</creatorcontrib><creatorcontrib>Ito, Takahiro</creatorcontrib><creatorcontrib>Fujiya, Mikihiro</creatorcontrib><creatorcontrib>Sakatani, Aki</creatorcontrib><creatorcontrib>Ikuta, Katsuya</creatorcontrib><title>Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Background/Aims. While biological drugs are useful for relieving the disease activity and preventing abdominal surgery in patients with Crohn’s disease (CD), it is unclear whether the use of biological drugs in CD patients with no history of abdominal surgery is appropriate. We evaluated the effects of infliximab and other factors on extending the duration until the first surgery in CD patients on a long-term basis. Methods. The clinical records of 104 CD patients were retrospectively investigated. The cumulative nonoperation rate until the first surgery was examined with regard to demographic factors and treatments. Results. The 50% nonoperative interval in the 104 CD patients was 107 months. The results of a univariate analysis revealed that a female gender, the colitis type of CD, and the administration of corticosteroids, immunomodulators, or infliximab were factors estimated to improve the cumulative nonoperative rate. A multivariate analysis showed that the colitis type and administration of infliximab were independent factors associated with a prolonged interval until the first surgery in the CD patients with no history of abdominal surgery. Conclusions. This study suggests that infliximab treatment extends the duration until the first surgery in CD patients with no history of abdominal surgery. The early use of infliximab before a patient undergoes abdominal surgery is therefore appropriate.</description><subject>Abdomen - physiopathology</subject><subject>Abdomen - surgery</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Child</subject><subject>Clinical Study</subject><subject>Crohn Disease - drug therapy</subject><subject>Crohn Disease - physiopathology</subject><subject>Crohn Disease - surgery</subject><subject>Female</subject><subject>Humans</subject><subject>Infliximab</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Preoperative Period</subject><subject>Treatment Outcome</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><recordid>eNqNkc1OGzEURq2qiCBgxb7yErVK8d_M2BukKiSAhFQkYMPGcmauGVcTD7U9Jex4DV6PJ8FpaER3eGPLPjq-934IHVDyndKiOGKE8iNZKaHoJ7TDOBXjkgr6eXPmfIT2Y_xF8pK0JKrcRiMmeEUlL3bQ7bm3nVu6hZnj6TKBbyJOLeCTIZjkeo8Hn1z392rmQkz4agh3EB6x8_gyE-BTxA8utXgS-ta_PD1HfOIimAh7aMuaLsL-276LbmbT68nZ-OLn6fnkx8W4FpKnsZkrag0zAhiIshHGKCsYI9BIy2VRKVVZIcqalY2xwvJGzWUlCa8apURBGN9Fx2vv_TBfQFPnkoLp9H3ITYVH3Run_3_xrtV3_R-d7VKWK8HhmyD0vweISS9crKHrjId-iJoKRSpOpKwy-m2N1qGPMYDdfEOJXgWiV4HodSCZ_vK-sg37b_wZ-LoGWucb8-A-ZoOMgDXvYE5Jwfgr9ISeIg</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Okamoto, Kotaro</creator><creator>Tanabe, Hiroki</creator><creator>Ohtake, Takaaki</creator><creator>Kono, Toru</creator><creator>Furukawa, Hiroyuki</creator><creator>Ashida, Toshifumi</creator><creator>Kohgo, Yutaka</creator><creator>Moriichi, Kentaro</creator><creator>Tominaga, Motoya</creator><creator>Kashima, Shin</creator><creator>Ueno, Nobuhiro</creator><creator>Inaba, Yuhei</creator><creator>Ito, Takahiro</creator><creator>Fujiya, Mikihiro</creator><creator>Sakatani, Aki</creator><creator>Ikuta, Katsuya</creator><general>Hindawi Publishing Corporation</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4321-7774</orcidid><orcidid>https://orcid.org/0000-0001-5448-4766</orcidid></search><sort><creationdate>20130101</creationdate><title>Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease</title><author>Okamoto, Kotaro ; Tanabe, Hiroki ; Ohtake, Takaaki ; Kono, Toru ; Furukawa, Hiroyuki ; Ashida, Toshifumi ; Kohgo, Yutaka ; Moriichi, Kentaro ; Tominaga, Motoya ; Kashima, Shin ; Ueno, Nobuhiro ; Inaba, Yuhei ; Ito, Takahiro ; Fujiya, Mikihiro ; Sakatani, Aki ; Ikuta, Katsuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-ab91fa2a4e2e46d4aa9f4220ed8f3857997f446c26daf4f3d9b878037d9945023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Abdomen - physiopathology</topic><topic>Abdomen - surgery</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Child</topic><topic>Clinical Study</topic><topic>Crohn Disease - drug therapy</topic><topic>Crohn Disease - physiopathology</topic><topic>Crohn Disease - surgery</topic><topic>Female</topic><topic>Humans</topic><topic>Infliximab</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Preoperative Period</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okamoto, Kotaro</creatorcontrib><creatorcontrib>Tanabe, Hiroki</creatorcontrib><creatorcontrib>Ohtake, Takaaki</creatorcontrib><creatorcontrib>Kono, Toru</creatorcontrib><creatorcontrib>Furukawa, Hiroyuki</creatorcontrib><creatorcontrib>Ashida, Toshifumi</creatorcontrib><creatorcontrib>Kohgo, Yutaka</creatorcontrib><creatorcontrib>Moriichi, Kentaro</creatorcontrib><creatorcontrib>Tominaga, Motoya</creatorcontrib><creatorcontrib>Kashima, Shin</creatorcontrib><creatorcontrib>Ueno, Nobuhiro</creatorcontrib><creatorcontrib>Inaba, Yuhei</creatorcontrib><creatorcontrib>Ito, Takahiro</creatorcontrib><creatorcontrib>Fujiya, Mikihiro</creatorcontrib><creatorcontrib>Sakatani, Aki</creatorcontrib><creatorcontrib>Ikuta, Katsuya</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okamoto, Kotaro</au><au>Tanabe, Hiroki</au><au>Ohtake, Takaaki</au><au>Kono, Toru</au><au>Furukawa, Hiroyuki</au><au>Ashida, Toshifumi</au><au>Kohgo, Yutaka</au><au>Moriichi, Kentaro</au><au>Tominaga, Motoya</au><au>Kashima, Shin</au><au>Ueno, Nobuhiro</au><au>Inaba, Yuhei</au><au>Ito, Takahiro</au><au>Fujiya, Mikihiro</au><au>Sakatani, Aki</au><au>Ikuta, Katsuya</au><au>Kuramochi, Hidekazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>2013</volume><issue>2013</issue><spage>1</spage><epage>5</epage><pages>1-5</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Background/Aims. While biological drugs are useful for relieving the disease activity and preventing abdominal surgery in patients with Crohn’s disease (CD), it is unclear whether the use of biological drugs in CD patients with no history of abdominal surgery is appropriate. We evaluated the effects of infliximab and other factors on extending the duration until the first surgery in CD patients on a long-term basis. Methods. The clinical records of 104 CD patients were retrospectively investigated. The cumulative nonoperation rate until the first surgery was examined with regard to demographic factors and treatments. Results. The 50% nonoperative interval in the 104 CD patients was 107 months. The results of a univariate analysis revealed that a female gender, the colitis type of CD, and the administration of corticosteroids, immunomodulators, or infliximab were factors estimated to improve the cumulative nonoperative rate. A multivariate analysis showed that the colitis type and administration of infliximab were independent factors associated with a prolonged interval until the first surgery in the CD patients with no history of abdominal surgery. Conclusions. This study suggests that infliximab treatment extends the duration until the first surgery in CD patients with no history of abdominal surgery. The early use of infliximab before a patient undergoes abdominal surgery is therefore appropriate.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>24371835</pmid><doi>10.1155/2013/879491</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-4321-7774</orcidid><orcidid>https://orcid.org/0000-0001-5448-4766</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2013-01, Vol.2013 (2013), p.1-5 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3858862 |
| source | MEDLINE; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Abdomen - physiopathology Abdomen - surgery Adolescent Adult Aged Antibodies, Monoclonal - administration & dosage Child Clinical Study Crohn Disease - drug therapy Crohn Disease - physiopathology Crohn Disease - surgery Female Humans Infliximab Male Middle Aged Preoperative Period Treatment Outcome |
| title | Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T01%3A48%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infliximab%20Extends%20the%20Duration%20until%20the%20First%20Surgery%20in%20Patients%20with%20Crohn%E2%80%99s%20Disease&rft.jtitle=BioMed%20research%20international&rft.au=Okamoto,%20Kotaro&rft.date=2013-01-01&rft.volume=2013&rft.issue=2013&rft.spage=1&rft.epage=5&rft.pages=1-5&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2013/879491&rft_dat=%3Cproquest_pubme%3E1490730887%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490730887&rft_id=info:pmid/24371835&rfr_iscdi=true |